Cellular Biomedicine Group, Inc.
(NASDAQ GS: CBMG)
Attention investors who purchased shares of Cellular Biomedicine Group, Inc. before August 12, 2020:
Rigrodsky & Long is investigating potential claims against the board of directors of Cellular Biomedicine Group, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by a consortium including CBMG CEO Bizuo (Tony) Liu and others.
Rigrodsky & Long, P.A. announces that it is investigating Cellular Biomedicine Group, Inc. (“CBMG”) (NASDAQ GS: CBMG) regarding possible breaches of fiduciary duties and other violations of law related to CBMG’s agreement to be acquired by a consortium headed by Bizuo (Tony) Liu, CBMG's CEO. Under the terms of the agreement, shareholders of CBMG will receive $19.75 in cash for each share of CBMG they own.
If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at firstname.lastname@example.org.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.